Screener / SEC EDGAR /CIK 0001638833 /10-K filed Mar 2, 2026, compared with Mar 7, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Hospitals

Surgery Partners, Inc. SGRY

Compare with peers Embed
The 10-K against last year's

70 changes: 7 added, 5 removed, 57 reworded, 1 quiet changes

10-K Mar 2, 2026 vs Mar 7, 2025

10-K 0001638833-26-000008 (Mar 2, 2026) vs 10-K 0001638833-25-000053 (Mar 7, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

179 paragraphs · 4 new · 33 reworded · 3 gone · 10-K Mar 2, 2026 against Mar 7, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 102 · 47% changed Every version of it
As a result of these and other covenants and restrictions, we may be limited in how we conduct our business. In addition, we may be required to maintain a specified financial maintenance ratio in connection with the Senior Indebtedness if the Revolver is utilized in excess of a specified threshold. The terms of any future indebtedness we may incur could include more restrictive covenants. We cannot assure you that we will be able to maintain compliance with these covenants in the future and, if we fail to do so, that we will be able to obtain waivers from the lenders and/or amend the covenants. Our failure to comply with the restrictive covenants described above as well as others contained in our future debt instruments from time to time could result in an event of default, which, if not cured or waived, could result in our being required to repay these borrowings before their maturity. If we are forced to refinance these borrowings on less favorable terms, our results of operations and financial condition could be adversely affected.
Paragraph 77 · 42% changed Every version of it
necessity and correctly applying diagnosis codes. Incorrect or incomplete documentation and billing information could result in non-payment for services rendered. The primary collection risks with respect to our patient receivables relate to patient accounts for which the primary third-party payor has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and co-payments) remain outstanding.
Paragraph 35 · 28% changed Every version of it
CMS to Medicare’s reimbursement policies; requirements for utilization review; and federal and state funding restrictions; any of which could materially adversely affect payments we receive from these government programs, as well as affect the timing of payments to our facilities.
Paragraph 154 · 27% changed Every version of it
All payors are increasingly conducting post-payment audits. For example, CMS has implemented the RAC program, involving Medicare claims audits nationwide, and employs MICs to perform post-payment audits of Medicaid claims and identify overpayments. In addition to RACs and MICs, the state Medicaid agencies and other contractors have increased their review activities. We are regularly subject to these external audits and we also perform both internal and third-party audits and monitoring.
Paragraph 144 · 25% changed Every version of it
We attempt to structure our relationship with physicians who refer to our surgical hospitals to meet an exception to the Stark Law where required, but the regulations implementing the exceptions are detailed and complex, and we cannot guarantee that every relationship complies fully with the Stark Law. We also believe that certain services provided by our managed physician network are covered by the Stark Law, but referrals for those services are exempt from the Stark Law under its "in-office ancillary services exception," among others.
Paragraph 57 · 20% changed Every version of it
may have to renegotiate, or risk losing, one or more of the facility’s private insurance contracts. We may also be unable to immediately collect the accounts receivable of an acquired facility while we align the payors’ payment systems and accounts with our own systems. Finally, certain transactions can require licensure changes which, in turn, result in disruptions in payment for services.
Paragraph 19 · 19% changed Every version of it
We •We cannot predict the effect that health care reform and other changes in healthcare laws, regulations, policies and government programs may have on our business, financial condition or results of operations.
Paragraph 135 · 17% changed Every version of it
A number of initiatives have been proposed during the past several years to reform various aspects of the health care system in the U.S. In the future, different interpretations or enforcement of existing or new laws and regulations could subject our current practices to allegations of impropriety or illegality, or could require us to make changes in our facilities, equipment, personnel, services, capital expenditure programs and operating expenses. In addition, some of the governmental and regulatory bodies that regulate us are considering or may in the future consider enhanced or new regulatory requirements. These authorities may also seek to exercise their supervisory or enforcement authority in new or more robust ways. All of these possibilities, if they occurred, could detrimentally affect the way we conduct our business and manage our capital, either of which, in turn, could have a material adverse effect on our business, prospects, results of operations and financial condition.

MD&A

86 paragraphs · 3 new · 33 reworded · 2 gone · 10-K Mar 2, 2026 against Mar 7, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 24 · 50% changed
revenues, net of contractual allowances adjustments and implicit price concessions, which we estimate concessions. Contractual adjustments and implicit price concessions are estimated based on existing contracts or the contractual agreements, discount policies and historical trend experience of our cash collections and historical write-offs. The estimated contractual write-offs. Contractual allowances adjustments are recorded recognized at the time of payment services being performed, with ASCs typically based on contractual agreements and surgical hospitals typically based on historical experience of cash collections and write-offs. Changes in estimated contractual adjustments are recorded in the period of change, with final adjustments, if any, typically at the time of billing for surgical hospitals and ASCs, respectively. payment.
Paragraph 80 · 44% changed
(3)This amount includes the reclassification of $7.5 million of unrealized gains out of accumulated OCI into income related to the de-designation of a portion of one of the Company's interest rate caps for the year ended December 31, 2022. This amount further includes fair value changes of undesignated derivatives for the years year ended December 31, 2024, 2023 and 2022. 2023.
Paragraph 10 · 44% changed
Our revenues consist of patient service revenues and other service revenues. Patient service revenues consist of revenue from our Surgical Facilities reportable segment. Specifically, patient service revenues include fees for surgical or diagnostic procedures performed at surgical facilities that we consolidate for financial reporting purposes, as well as for patient visits to our physician practices, anesthesia services, pharmacy services and diagnostic screens ordered by our physicians. Other service revenues include management and administrative service fees derived from our non-consolidated facilities that we account for under the equity method, management of surgical facilities and physician practices in which we do not own an interest, management services we provide to physician practices for which we are not required to provide capital or additional assets and other non-patient services.
Paragraph 78 · 42% changed
(1)This amount includes diligence, transaction and integration costs related to acquisitions (both completed and in the pipeline) and divested facilities (collectively "M&A costs") of $100.1 $55.2 million, $61.7 $76.4 million and $47.5 $49.3 million for the years ended December 31, 2024, 2023 2025, 2024 and 2022, 2023, respectively. The $100.1 million for the year ended December 31, 2024, includes approximately $10.7 million of costs associated with evaluating strategic alternatives. This amount further also includes start-up costs related to de novo surgical facilities other costs, including severance, IT implementation, and revenue cycle standardization of $7.9 $18.7 million, $3.2 $23.7 million and $1.1 $12.4 million for the years ended December 31, 2024, 2023 2025, 2024 and 2022, 2023, respectively.
Paragraph 27 · 41% changed
Our patient service revenues and other receivables Accounts receivable from third-party payors are recorded net of contractual allowances and implicit price concessions, which are estimated based on established fee schedules, relationships with payors, procedure statistics and other objective information including the historical trend of cash collections and contractual write-offs. Contractual allowances adjustments and implicit price concessions are recorded estimated based on contractual agreements, discount policies and historical experience of cash collections and historical write-offs. The estimated contractual adjustments and implicit price concessions are recognized at the time of payment services being performed, with ASCs generally based on contractual agreements and surgical hospitals generally based on historical experience of cash collections and write-offs. Changes in estimated contractual adjustments and implicit price concessions are recorded in the period of change, with final adjustments, if any, typically at the time of billing for surgical hospitals and ambulatory surgical centers, respectively. While changes in estimated reimbursement from third-party payors remain a possibility, we expect that any such changes would be minimal and, therefore, would not have a material effect on our financial condition or results of operations. payment.
Paragraph 34 · 39% changed
We recorded a valuation allowance against our deferred tax assets at December 31, 2024 and 2023 totaling $284.7 million and $150.1 million, respectively. The valuation allowance has been established for certain deferred tax assets for which we believe it is more likely than not that the tax benefits will not be realized. Our income tax expense and/or other comprehensive income in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.
Paragraph 74 · 37% changed
Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be considered in isolation or as a substitute for net income, operating income or any other measure calculated in accordance with GAAP. The items excluded from this non-GAAP metric are significant components in understanding and evaluating our financial performance. We believe such adjustments are appropriate, as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. Our calculation of Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We use Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by our management to assess operating performance, make business decisions and allocate resources. non-
Paragraph 61 · 29% changed
Net cash provided by used in financing activities for the year ended December 31, 2024 2025 was $262.0 $57.3 million compared to net cash used provided by financing activities of $155.2 $262.0 million for the year ended December 31, 2023. 2024. The increase decrease of $417.2 $319.3 million was primarily driven by the difference in the amount of net proceeds received from the issuance and sale of $425.0 million and $800.0 million in senior unsecured notes, partially offset by notes for the redemption of all the Existing Notes (as discussed in the following section). years ended December 31, 2025 and 2024, respectively. The remaining increase decrease was due to net borrowings on the Revolver used an increase in distributions to fund acquisitions completed during the year ended December 31, 2024. non-controlling interest holders of $55.5 million.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors156 words changed in this paragraph; it is 41% similar to last year's version.
As of December 31, 2024, 2025, we and our subsidiaries had approximately $3.4 $3.7 billion aggregate principal amount of indebtedness outstanding, which includes approximately $1.4 billion principal amount of senior secured term loans (the "Term Loan") outstanding and $800.0 $1,225.0 million senior unsecured notes due 2032 (the "2032 Unsecured Notes"). As of December 31, 2024, 2025, we had $192.0 million of no outstanding borrowings under our $703.8 million senior secured revolving credit facility (the "Revolver" and, together with the Term Loan, the "New Secured Credit Facilities" and, together with the 2032 Unsecured Notes, the "Senior Indebtedness"). After giving effect to the $10.3 million principal amount of outstanding letters of credit issued under our Revolver, we had $501.5 million of unused commitments available to be borrowed under the Revolver. In addition to the Senior Indebtedness, our aggregate principal amount of indebtedness outstanding includes approximately $1.0 billion of notes payable and finance lease obligations primarily related to property and equipment for operations. Our level of indebtedness increases the risk that we may be unable to generate cash sufficient to pay amounts due in respect of our indebtedness. In addition, subject to applicable restrictions under our Senior Indebtedness, we may incur significant additional indebtedness, which may be secured, from time to time, which could have important consequences, including:

Source: Item 1A, 10-K 0001638833-26-000008 vs Item 1A, 10-K 0001638833-25-000053

Accounting Policies136 words changed in this paragraph; it is 46% similar to last year's version.
In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40), 22-40): Disaggregation of Income Statement Expenses, which requires disaggregated disclosure of entities to provide enhanced disclosures related to certain expense categories included in income statement line items that contain specified expense categories, such as purchases captions. The ASU aims to increase transparency and provide investors with more detailed information about the nature of inventory, employee compensation, depreciation, amortization, and depletion. This expenses reported on the face of the income statement. The new standard does not change the requirements for the presentation of expenses on the face of the income statement. The ASU is effective for fiscal years annual reporting periods beginning after December 15, 2026 and for interim reporting periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact this ASU will may have on our its financial statements and related disclosures.

Source: 10-K text, Note 1 – Organization and Summary of Accounting Policies, 10-K 0001638833-26-000008 vs 10-K text, Note 1 – Organization and Summary of Accounting Policies, 10-K 0001638833-25-000053

MD&A134 words changed in this paragraph; it is 43% similar to last year's version.
Our patient service revenues and other receivables Accounts receivable from third-party payors are recorded net of contractual allowances and implicit price concessions, which are estimated based on established fee schedules, relationships with payors, procedure statistics and other objective information including the historical trend of cash collections and contractual write-offs. Contractual allowances adjustments and implicit price concessions are recorded estimated based on contractual agreements, discount policies and historical experience of cash collections and historical write-offs. The estimated contractual adjustments and implicit price concessions are recognized at the time of payment services being performed, with ASCs generally based on contractual agreements and surgical hospitals generally based on historical experience of cash collections and write-offs. Changes in estimated contractual adjustments and implicit price concessions are recorded in the period of change, with final adjustments, if any, typically at the time of billing for surgical hospitals and ambulatory surgical centers, respectively. While changes in estimated reimbursement from third-party payors remain a possibility, we expect that any such changes would be minimal and, therefore, would not have a material effect on our financial condition or results of operations. payment.

Source: Item 7, 10-K 0001638833-26-000008 vs Item 7, 10-K 0001638833-25-000053

Legal Proceedings16 words changed in this paragraph; it is 91% similar to last year's version.
In May 2023, we experienced a cybersecurity incident that temporarily disrupted certain facilities in our Idaho market. We estimate that this incident had an adverse pre-tax impact of approximately $ 8 million during the year ended December 31, 2023. This estimate includes lost revenue from the associated business interruption and other related expenses. We have filed a claim with the insurance carrier related to this incident. Insurance recoveries of $ 6.5 million were recognized during each of the year years ended December 31, 2024 with no comparable activity in the prior year. and December 31, 2025.

Source: Item 3, via Note 13 – Commitments and Contingencies, 10-K 0001638833-26-000008 vs Item 3, via Note 13 – Commitments and Contingencies, 10-K 0001638833-25-000053

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of SGRY's Risk Factors and MD&A, 10-K Mar 2, 2026 against 10-K Mar 7, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
As of December 31, 2025, we and our subsidiaries had approximately $3.7 billion aggregate principal amount of indebtedness outstanding, which includes approximately $1.4 billion principal amount of senior secured term loans (the "Term Loan") outstanding and $1,225.0 million senior unsecured notes due 2032 (the "2032 Unsecured Notes"). As of December 31, 2025, we had no outstanding
Read it in 10-K Mar 2, 2026 at sec.gov
AddedRisk Factors
compliance with the diverse privacy requirements in all of the jurisdictions in which we do business. If we fail to comply with HIPAA or similar state laws, we could incur substantial civil monetary or criminal penalties.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedRisk Factors
Over the past several years, various laws and regulations lengthened the enrollment period, expanded income eligibility, and reduced premium caps for subsidies for individuals purchasing Affordable Care Act coverage through state and federal marketplaces. However, several of these provisions – notably, those relating to premium caps for subsidies – expired on December 31, 2025. The failure of Congress to renew these subsidies through legislative action is widely anticipated to result in significant increases in premiums, potentially leading to decreased enrollment and a corresponding rise in the number of uninsured individuals or a shift of individuals from commercial coverage to government program coverage in 2026. As a direct effect of these changes, the Company may experience decreased patient volumes, reduced revenues and an increase in uncompensated care, which would adversely affect the Company’s results of operations and cash flows. We cannot predict whether or how the Congress may further extend (or decline to extend) or modify provisions of or relating to the Affordable Care Act or other laws affecting the healthcare industry generally, nor can we predict how the current administration will influence, promulgate or implement rules, regulations or executive orders that affect the healthcare industry directly or indirectly (including, for example, through changes resulting from the provisions of the OBBBA). We may also experience potential impacts on our business, in ways we cannot anticipate, from healthcare-related policy changes at the state level. Some federal and state changes, initiatives and requirements could, among other things, negatively impact our patient volumes, case mix and revenue mix, increase our operating costs, adversely affect the reimbursement we receive for our services, impact our competitive position or require us to expend resources to modify certain aspects of our operations, any of which could have an adverse effect on our financial condition, results of operations or cash flows. Furthermore, we cannot predict the impact healthcare policy risks and uncertainties may have on the trading price of our common stock.
Read it in 10-K Mar 2, 2026 at sec.gov
RemovedRisk Factors
The Affordable Care Act has changed and continues to change how health care services are covered, delivered and reimbursed through, among other things, expanded coverage of uninsured individuals, reduced growth in Medicare program spending and the establishment and expansion of programs tying reimbursement to quality and clinical integration. The Affordable Care Act also reforms certain aspects of health insurance, quality of care and fraud and abuse enforcement.
Read it in 10-K Mar 7, 2025 at sec.gov
RemovedRisk Factors
Our amended and restated certificate of incorporation (the "Certificate of Incorporation") provides that, subject to certain exceptions and to the fullest extent permitted by applicable law, the Court of Chancery of the State of Delaware (the "Court of Chancery") will be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a
Read it in 10-K Mar 7, 2025 at sec.gov
RewordedRisk Factors
In addition, we are unable to predict the results of an increasing trend towards value based payment on our reimbursement.Therefore, the results of our individual affiliated facilities, including facilities that are material to our results, may be volatile, which could result in a material adverse effect on our business, prospects, results of operations and financial condition. reimbursement.
Read it in 10-K Mar 2, 2026 at sec.gov
Show the other 29
RewordedRisk Factors
To the extent our patient assistance programs or other discount policies are found to be inconsistent with applicable laws, we may be required to restructure or discontinue such programs, or be subject to other significant penalties.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
In addition, we are unable to predict the results of an increasing trend towards value based payment on our reimbursement.Therefore, Therefore, the results of our individual affiliated facilities, including facilities that are material to our results, may be volatile, which could result in a material adverse effect on our business, prospects, results of operations and financial condition.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
For example, HHS issued a Notice of Proposed Rulemaking on January 6, 2025, which proposes changes to the HIPAA security regulations aimed at enhancing cybersecurity protections in the healthcare sector. sector; however, as of December 31, 2025, HHS had yet to publish a final rule formalizing the January 2025 proposals.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
The amounts that we receive from the Medicare and Medicaid programs for our services are subject to statutory and regulatory changes, administrative rulings, interpretations and determinations concerning patient eligibility requirements, funding levels and the method of calculating payments or reimbursements, among other things; refinements to the Medicare Ambulatory Surgery Center payment system and refinements made by CMS to Medicare’s reimbursement policies; requirements for utilization review; and federal and state funding restrictions; any of which
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
Higher numbers of unemployed individuals generally translates into more individuals without health care insurance to help pay for procedures, thereby increasing the potential for persons to elect not to have procedures performed.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
We derived approximately 43%, 41% and 42% of our revenue from government payors, including Medicare and Medicaid programs in 2025, 2024 and 42% in both 2023 and 2022. 2023, respectively.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
Although most of our intercompany loans are secured by the assets of the partnership or limited liability company, LLC, the physicians and physician groups that own an interest in these partnerships and limited liability companies LLCs generally do not guarantee a pro rata amount of this debt or the other obligations of these partnerships and limited liability companies. LLCs.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
We cannot predict the effect that health care reform and other changes in healthcare laws, regulations, policies and government programs may have on our business, financial condition or results of operations.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
We generally hold our ownership interests in facilities through LPs, LLPs, GPs, and LLCs or limited liability partnerships ("LLPs") in which we maintain an ownership interest along with physicians and, in some cases, both physicians and health systems.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
On July 4, 2025, Congress passed the One Big Beautiful Bill Act (the “OBBBA”), which introduced significant changes to federally funded healthcare programs, including Medicaid, Medicare, and the Affordable Care Act. While such changes are projected to reduce overall healthcare spending and increase regulatory burdens in certain jurisdictions in which the Company operates, they are not expected to materially impact the Company's financial statements.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
The OBBBA also makes permanent key elements of the Tax Cuts and Jobs Act including, among others, 100% bonus depreciation and the business interest expense limitations. The Company’s tax provision for the year ended December 31, 2025, incorporates the effects of these tax law changes.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
On December 16, 2025, we completed the issuance and sale of $425.0 million in aggregate principal amount of senior unsecured notes due 2032 at 101.00% of the principal amount. The notes were issued as part of the same series as the existing 2032 Unsecured Notes originally issued in April 2024, and have the same terms.
Read it in 10-K Mar 2, 2026 at sec.gov
RemovedMD&A
On April 10, 2024, we completed the issuance and sale of $800.0 million in aggregate principal amount of senior unsecured notes due 2032 (the "2032 Notes"). The 2032 Notes bear interest at an annual rate of 7.250% per year, payable semi-annually on April 15 and October 15 of each year, beginning on October 15, 2024. Proceeds from sale of the 2032 Notes were used (i) to redeem all of the outstanding 2025 Notes and 2027 Notes, (ii) to pay accrued interest on the Existing Notes through, but not including, April 25, 2024, (iii) to pay related fees and expenses in connection with the offering of the 2032 Notes and redemption of the Existing Notes, and (iv) for general corporate purposes, including to fund future acquisitions.
Read it in 10-K Mar 7, 2025 at sec.gov
RewordedMD&A
The increase decrease of $417.2 $319.3 million was primarily driven by the difference in the amount of net proceeds received from the issuance and sale of $425.0 million and $800.0 million in senior unsecured notes, partially offset by notes for the redemption of all the Existing Notes (as discussed in the following section). years ended December 31, 2025 and 2024, respectively.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
Other service revenues include management and administrative service fees derived from our non-consolidated facilities that we account for under the equity method, management of surgical facilities and physician practices in which we do not own an interest, management services we provide to physician practices for which we are not required to provide capital or additional assets and other non-patient services.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
The increase decrease in income tax (expense) benefit expense was primarily driven by an increase in 2024 being the valuation allowance as a result of initial year the Company being was in a cumulative three-year pre-tax loss position at December 31, 2024. and thereby recorded a valuation allowance against its net operating loss carry-forward.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
Net income attributable to non-controlling interests (176.8) (180.6) (147.2) (141.6) Depreciation and amortization 176.0 152.6 118.1 114.8 Interest expense, net 272.6 201.7 193.0 234.9 Equity-based compensation expense 14.8 33.3 17.7 18.4 Transaction, integration and acquisition costs (1) 108.0 64.9 48.6 73.9 100.1 61.7 De novo start-up costs 6.7 7.9 3.2 Net loss on disposals, consolidations and deconsolidations 30.4 40.6 14.4 11.1 Litigation settlements and regulatory change impact (2) 10.4 3.1 17.5 (24.7) Loss on debt extinguishment 1.3 5.1 15.5 14.9 Undesignated derivative activity (3) — — 0.6 (8.0) Other (4) — (2.7) 8.6 1.5 Adjusted EBITDA $ 526.2 $ 508.2 $ 438.1 $ 380.2
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
Non-cash interest expense, net (6.5) (9.6) Non-cash lease expense (38.9) (37.8) Deferred income taxes (131.5) (16.7) Equity in earnings of unconsolidated affiliates, net of distributions received 2.0 0.8 Changes in operating assets and liabilities, net of acquisitions and divestitures 118.9 110.4 Income tax expense 134.6 18.0 Net income attributable to non-controlling interests (180.6) (176.8) Interest expense, net 201.7 272.6 Transaction, integration and acquisition costs 108.0 73.9 De novo start-up costs 6.7 Litigation settlements and other litigation costs 3.1 Other (1) (2.7) 10.4 Acquisitions and synergies (2) 58.4 (1) 52.0 Credit Agreement EBITDA $ 566.6 578.2
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
The 2024 2025 Refinancing Term Loans replace or refinance in full all of the existing term loans outstanding under the Credit Agreement (as in effect immediately prior to the Second Amendment), and refinance in full all of the existing revolving credit commitments and outstanding revolving loans under the Credit Agreement (as in effect immediately prior to the Second Amendment), all as further set forth in the Second Amendment.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
Cost of revenues 2,543.7 2,368.7 2,095.8 1,964.4 General and administrative expenses 118.2 138.7 120.9 102.2 Depreciation and amortization 176.0 152.6 118.1 114.8 Transaction and integration costs 73.9 100.1 61.7 47.5 Net loss on disposals, consolidations and deconsolidations 30.4 40.6 14.4 11.1 Equity in earnings of unconsolidated affiliates (22.9) (19.5) (14.2) (12.5) Litigation settlements 7.3 (0.8) 10.6 (29.3) Loss on debt extinguishment 1.3 5.1 15.5 14.9 Other income (8.7) (20.0) (7.5) (19.0) 2,919.2 2,765.5 2,415.3 2,194.1 Operating income 389.5 348.8 328.0 345.2 Interest expense, net (272.6) (201.7) (193.0) (234.9) Income before income taxes 116.9 147.1 135.0 110.3 Income tax (expense) benefit (18.0) (134.6) 0.3 (23.3) Net income 98.9 12.5 135.3 87.0 Less:
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
(1)This amount includes diligence, transaction and integration costs related to acquisitions (both completed and in the pipeline) and divested facilities (collectively "M&A costs") of $100.1 $55.2 million, $61.7 $76.4 million and $47.5 $49.3 million for the years ended December 31, 2024, 2023 2025, 2024 and 2022, 2023, respectively.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
(1)This This amount also includes transaction other costs, including severance, IT implementation, and integration costs revenue cycle standardization of $100.1 $18.7 million, $61.7 $23.7 million and $47.5 $12.4 million for the years ended December 31, 2024, 2023 2025, 2024 and 2022, 2023, respectively.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
Our income tax expense and/or other comprehensive income in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
Interest expense, net was $272.6 million for the year ended December 31, 2025 compared to $201.7 million for the year ended December 31, 2024 compared to $193.0 million for the year ended December 31, 2023. 2024.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
Our cash flows provided by operating activities was $274.3 million for the year ended December 31, 2025 compared to $300.1 million for the year ended December 31, 2024 compared to $293.8 million for the year ended December 31, 2023. 2024.
Read it in 10-K Mar 2, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SGRY/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.